Edwin H Kim1, Luanna Yang2, Ping Ye2, Rishu Guo2, Quefeng Li3, Michael D Kulis2, A Wesley Burks2. 1. Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC. Electronic address: edwinkim@email.unc.edu. 2. Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, University of North Carolina School of Medicine, Chapel Hill, NC. 3. Department of Biostatistics, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC.
Abstract
BACKGROUND:Peanut sublingual immunotherapy (SLIT) for 1 year has been shown to induce modest clinical desensitization in allergic children. Studies of oral immunotherapy, epicutaneous immunotherapy, and SLIT have suggested additional benefit with extended treatment. OBJECTIVE: We sought to investigate the safety, clinical effectiveness, and immunologic changes with long-term SLIT in children with peanut allergy. METHODS:Children with peanut allergy aged 1 to 11 years underwentextended maintenance SLIT with 2 mg/d peanut protein for up to 5 years. Subjects with peanut skin test wheals of less than 5 mm and peanut-specific IgE levels of less than 15 kU/L were allowed to discontinue therapy early. Desensitization was assessed through a double-blind, placebo-controlled food challenge (DBPCFC) with up to 5000 mg of peanut protein after completion of SLIT dosing. Sustained unresponsiveness was further assessed by using identical DBPCFCs after 2 to 4 weeks without peanut exposure. RESULTS:Thirty-seven of 48 subjects completed 3 to 5 years of peanut SLIT, with 67% (32/48) successfully consuming 750 mg or more during DBPCFCs. Furthermore, 25% (12/48) passed the 5000-mg DBPCFC without clinical symptoms, with 10 of these 12 demonstrating sustained unresponsiveness after 2 to 4 weeks. Side effects were reported with 4.8% of doses, with transient oropharyngeal itching reported most commonly. Side effects requiring antihistamine treatment were uncommon (0.21%), and no epinephrine was administered. Peanut skin test wheals, peanut-specific IgE levels, and basophil activation decreased significantly, and peanut-specific IgG4 levels increased significantly after peanut SLIT. CONCLUSION: Extended-therapy peanut SLIT provided clinically meaningful desensitization in the majority of children with peanut allergy that was balanced with ease of administration and a favorable safety profile.
RCT Entities:
BACKGROUND:Peanut sublingual immunotherapy (SLIT) for 1 year has been shown to induce modest clinical desensitization in allergicchildren. Studies of oral immunotherapy, epicutaneous immunotherapy, and SLIT have suggested additional benefit with extended treatment. OBJECTIVE: We sought to investigate the safety, clinical effectiveness, and immunologic changes with long-term SLIT in children with peanutallergy. METHODS:Children with peanutallergy aged 1 to 11 years underwent extended maintenance SLIT with 2 mg/d peanut protein for up to 5 years. Subjects with peanut skin test wheals of less than 5 mm and peanut-specific IgE levels of less than 15 kU/L were allowed to discontinue therapy early. Desensitization was assessed through a double-blind, placebo-controlled food challenge (DBPCFC) with up to 5000 mg of peanut protein after completion of SLIT dosing. Sustained unresponsiveness was further assessed by using identical DBPCFCs after 2 to 4 weeks without peanut exposure. RESULTS: Thirty-seven of 48 subjects completed 3 to 5 years of peanut SLIT, with 67% (32/48) successfully consuming 750 mg or more during DBPCFCs. Furthermore, 25% (12/48) passed the 5000-mg DBPCFC without clinical symptoms, with 10 of these 12 demonstrating sustained unresponsiveness after 2 to 4 weeks. Side effects were reported with 4.8% of doses, with transient oropharyngeal itching reported most commonly. Side effects requiring antihistamine treatment were uncommon (0.21%), and no epinephrine was administered. Peanut skin test wheals, peanut-specific IgE levels, and basophil activation decreased significantly, and peanut-specific IgG4 levels increased significantly after peanut SLIT. CONCLUSION: Extended-therapy peanut SLIT provided clinically meaningful desensitization in the majority of children with peanutallergy that was balanced with ease of administration and a favorable safety profile.
Authors: Corinne A Keet; Pamela A Frischmeyer-Guerrerio; Ananth Thyagarajan; John T Schroeder; Robert G Hamilton; Stephen Boden; Pamela Steele; Sarah Driggers; A Wesley Burks; Robert A Wood Journal: J Allergy Clin Immunol Date: 2011-11-30 Impact factor: 10.793
Authors: Edwin H Kim; J Andrew Bird; Michael Kulis; Susan Laubach; Laurent Pons; Wayne Shreffler; Pamela Steele; Janet Kamilaris; Brian Vickery; A Wesley Burks Journal: J Allergy Clin Immunol Date: 2011-02-01 Impact factor: 10.793
Authors: David M Fleischer; Tamara T Perry; Dan Atkins; Robert A Wood; A Wesley Burks; Stacie M Jones; Alice K Henning; Donald Stablein; Hugh A Sampson; Scott H Sicherer Journal: Pediatrics Date: 2012-06-25 Impact factor: 7.124
Authors: David M Fleischer; Matthew Greenhawt; Gordon Sussman; Philippe Bégin; Anna Nowak-Wegrzyn; Daniel Petroni; Kirsten Beyer; Terri Brown-Whitehorn; Jacques Hebert; Jonathan O'B Hourihane; Dianne E Campbell; Stephanie Leonard; R Sharon Chinthrajah; Jacqueline A Pongracic; Stacie M Jones; Lars Lange; Hey Chong; Todd D Green; Robert Wood; Amarjit Cheema; Susan L Prescott; Peter Smith; William Yang; Edmond S Chan; Aideen Byrne; Amal Assa'ad; J Andrew Bird; Edwin H Kim; Lynda Schneider; Carla M Davis; Bruce J Lanser; Romain Lambert; Wayne Shreffler Journal: JAMA Date: 2019-03-12 Impact factor: 56.272
Authors: Mary E Bollinger; Lynnda M Dahlquist; Kim Mudd; Claire Sonntag; Lindsay Dillinger; Kristine McKenna Journal: Ann Allergy Asthma Immunol Date: 2006-03 Impact factor: 6.347
Authors: A Wesley Burks; Robert A Wood; Stacie M Jones; Scott H Sicherer; David M Fleischer; Amy M Scurlock; Brian P Vickery; Andrew H Liu; Alice K Henning; Robert Lindblad; Peter Dawson; Marshall Plaut; Hugh A Sampson Journal: J Allergy Clin Immunol Date: 2015-02-03 Impact factor: 10.793
Authors: David M Fleischer; A Wesley Burks; Brian P Vickery; Amy M Scurlock; Robert A Wood; Stacie M Jones; Scott H Sicherer; Andrew H Liu; Donald Stablein; Alice K Henning; Lloyd Mayer; Robert Lindblad; Marshall Plaut; Hugh A Sampson Journal: J Allergy Clin Immunol Date: 2013-01 Impact factor: 10.793
Authors: Natasha Purington; R Sharon Chinthrajah; Andrew Long; Sayantani Sindher; Sandra Andorf; Katherine O'Laughlin; Margaret A Woch; Alexandra Scheiber; Amal Assa'ad; Jacqueline Pongracic; Jonathan M Spergel; Jonathan Tam; Stephen Tilles; Julie Wang; Stephen J Galli; Manisha Desai; Kari C Nadeau Journal: Front Immunol Date: 2018-09-21 Impact factor: 7.561
Authors: Shiteng Duan; Britni M Arlian; Corwin M Nycholat; Yadong Wei; Hiroaki Tateno; Scott A Smith; Matthew S Macauley; Zhou Zhu; Bruce S Bochner; James C Paulson Journal: J Immunol Date: 2021-04-28 Impact factor: 5.422
Authors: Amy M Scurlock; A Wesley Burks; Scott H Sicherer; Donald Y M Leung; Edwin H Kim; Alice K Henning; Peter Dawson; Robert W Lindblad; M Cecilia Berin; Christine B Cho; Wendy F Davidson; Marshall Plaut; Hugh A Sampson; Robert A Wood; Stacie M Jones Journal: J Allergy Clin Immunol Date: 2020-12-05 Impact factor: 10.793
Authors: Cristobalina Mayorga; Francisca Palomares; José A Cañas; Natalia Pérez-Sánchez; Rafael Núñez; María José Torres; Francisca Gómez Journal: Foods Date: 2021-05-10